Defective Drug Litigation Funding

Have A Defective Drug Lawsuit? Need Cash Now?

TriMark Legal Funding provides lawsuit settlement cash advances on defective drug lawsuits nationwide.

TriMark Legal Funding is one of America’s top-rated lawsuit funding companies. We provide low-cost pre-settlement lawsuit loans to injury victims with defective drug lawsuits nationwide.


It’s Fast, Free & Easy To Qualify For Legal Funding

With each new pharmaceutical lawsuit, new light is shed on the ever-blurring lines between consumer protection and the FDA.

Defective Drug Lawsuit Loans

Not to mention the fading line between consumer safety and the ever-widening chasm of corporate greed, non-accountability and irresponsibility.

Pharmaceutical lawsuits are nothing new. What is new, and quite troubling however, is the ever-increasing size, scope, lethality and regularity with which new defective drug lawsuits are being introduced.

Perhaps most disturbing of all is the growing trend of MDL drug lawsuits being brought against pharmaceutical companies who are often shown to have been fully aware that their products had serious, even deadly side effects, but chose to ignore the human costs and market them anyway because of the multi-billion dollar profit potential. They just fail to provide adequate consumer warnings.

When did that become okay? Isn’t litigation meant to punish the offenders? If so, why does this trend seem to be gaining momentum instead of losing it? The all-too-obvious rationale is as outrageous as it is unconscionable; pursue the almighty dollar no matter the cost in human lives and suffering.

The pattern so far has been easy enough to spot; big pharmaceuticals earn tens of billions of dollars in profits by mass marketing a new drug for a few years and then write off the human losses and inevitable litigation expenses as simply the cost of doing business.

Historically, multi-billion-dollar litigation and settlement expenses tend to consume only a tiny fraction of a heavily-marketed pharmaceutical product’s overall profit run. So companies retain billions in profit after the dust settles; not much of an effective punishment or deterrent.

In addition, this provides zero incentive for pharmaceuticals companies to act responsibly or police themselves. To the contrary, it provides an enormous and clearly irresistible financial incentive to continue this despicable practice unabated.

Call (877) 932-2628 and speak with one of our funding experts today.

Legal Funding FAQ

❓ Q: What Is Legal Funding?

A: Legal funding is a risk-free cash advance that provides immediate financial relief to injured plaintiffs. They’re easy to qualify for, there are no credit checks, and they are only repaid after the case is resolved successfully.

❓ Q: How Much Does Legal Funding Cost?

A: If you’re thinking about getting a lawsuit cash advance on your case, it makes sense to be concerned about the cost.

The short answer is “it depends”. Read more

Over the years, TriMark Legal Funding has amassed an ever-expanding trove of excellent articles where you can learn more about legal funding. Here are a few examples:

  • Article List 1
  • Article List 2

See All of Our Articles

Get Legal Funding Now

Leave this field blank

To Get Started,

Please fill out the form to receive your free consultation. Or if you feel more comfortable sharing your information over the phone, please call us anytime:

(877) 932-2628

Leave this field blank

We will never sell or rent your information. We guarantee any information you provide, either on this website or over the phone, is kept confidential, protected, and secure in compliance with our strict Privacy Policy.


Latest Developments in Defective Drug Litigation…

Follow These Tips to Create Your Estate Plan  Legal Scoops… Read more
What is Zantac? Zantac is a popular OTC (over-the-counter) drug that is taken to relieve and prevent heartburn. It is also used to treat indigestion, acid reflux, and a variety of other health issues associated with GERD (gastroesophageal reflux disease), and it can be prescribed by a physician to treat any of these disorders. In early 2020, the FDA issued a recall on Zantac due to the fact that its active ingredient ranitidine may be linked to the development of certain cancers, including stomach, colon, and bladder cancers. Ranitidine Explained Prior to April 2020, the main ingredient in Zantac (and some other antacids) was ranitidine, which is an H2 blocker (histamine-2 antagonist). The purpose of H2 blockers in antacids is to prevent certain cells in … Read more
A three-year study of more than 1,000 patients found that the risk of delayed intracranial hemorrhage and death following head trauma was significantly higher for adults taking older blood thinning medications including clopidogrel (Plavix) and warfarin (Coumadin), according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA). The effects of newer blood thinners such as Pradaxa and Xarelto were not included in the report. Taking aspirin concurrently with any blood thinner may increase the risk of delayed hemorrhage. Intracranial hemorrhage occurs when blood vessels within the brain rupture, releasing blood into the brain tissue. In a delayed traumatic intracranial hemorrhage, bleeding in the brain occurs after the initial trauma, usually within 48 hours, after an initial negative head CT. High blood pressure, head injury and the use of blood thinners are known causes of intracranial hemorrhage. As the population ages, the prevalence of patients taking blood… Read more
McKinsey & Company, the consultant to blue-chip corporations and governments around the world, has agreed to pay nearly $600 million to settle investigations into its role in helping “turbocharge” opioid sales, a rare instance of it being held publicly accountable for its work with clients. The firm has reached a $573 million agreement with attorneys general in 47 states, the District of Columbia and five territories, according to a court filing in Massachusetts on Thursday. Separate deals were announced in Washington State, for $13 million, and in West Virginia, for $10 million. Nevada, not party to the agreements, will continue to pursue its opioid investigation, according to the attorney general’s office. The settlements come after lawsuits unearthed a trove of documents showing how McKinsey worked to drive sales of Purdue Pharma’s OxyContin painkiller amid an opioid crisis in the United States that has contributed to the deaths of more than… Read more
Four large pharmacy chains are set to face their first trial over the deadly U.S. opioid epidemic, creating new pressure to reach settlements with state and local governments who accuse them of contributing to the public health crisis. The Ohio counties of Lake and Trumbull allege that oversight failures at pharmacies run by Walgreens Boots Alliance Inc, CVS Health Corp, Walmart Inc and Giant Eagle Inc led to excessive amounts of opioid pills in their communities. Lawyers for the counties and companies are set to deliver opening statements on Monday to a federal jury in Cleveland, where thousands of similar lawsuits against pharmaceutical companies, drug distributors and pharmacies are pending. More than 3,300 cases have been brought largely by state and local governments seeking to hold the companies responsible for an opioid abuse epidemic that U.S. government data shows led to nearly 500,000 overdose deaths from 1999 to 2019…. Read more
7 Key Details As Pharmacy Giants Head To 1st Opioid Trial  Law360… Read more
Endo's Attys In 'Career-Wrecking' Peril As Opioid Woes Grow  Law360… Read more
Rite Aid Corp affiliates have settled claims by two Ohio counties that it contributed to the opioid addiction epidemic, just over a month before the case was set to go to trial. The pharmacy chain operator and Lake and Trumbull counties disclosed the settlement in a motion filed Wednesday in federal court in Cleveland, Ohio, to sever Rite Aid from the case. They did not reveal terms of the deal, which must be approved by Lake County Commissioners and Trumbull County Commissioners. U.S. District Judge Dan Polster granted the motion on Thursday…. Read more
States, Cities Eye $26 Billion Deal: Opioid Litigation Explained  Bloomberg Law… Read more
Drugmaker Endo settles opioid claims by Tennessee counties, cities for $35 mln  Reuters… Read more
Despite Fanfare, $26B Opioid Offer Far From Finish Line  Law360… Read more
Opioid distributors, J&J near settlement to resolve thousands of cases  The Washington Post… Read more
Purdue bankruptcy watchdog says protections benefiting Sacklers are 'illegal'  Reuters… Read more
Product Liability Cases To Watch: Midyear Review  Law360… Read more
Key Opioid Trials To Watch As Cases Heat Up Nationwide  Law360… Read more
Chicago Pushes For Opioid Trial But Pharma Wants More Time  Law360… Read more
Oldest Opioid Suit, An MDL Bellwether, Evades Latest Assault  Law360… Read more
Drug companies, plaintiffs close in on $26B deal to settle opioid lawsuits  The Washington Post… Read more
Pa. Supreme Court Ruling Tees Up Possible Punitive Damages Phase of $70M Risperdal Verdict | The Legal Intelligencer  Law.com… Read more
The federal judge handling the $775 million settlement over the blood thinner Xarelto has established a committee of five attorneys to assess how up to $93 million set aside for leading plaintiffs firms should be doled out. U.S. District Judge Eldon Fallon of the Eastern District of Louisiana tapped Pensacola, Florida, attorney Brian Barr of Levin Papantonio Thomas Mitchell Rafferty & Proctor; Andy Birchfield of Beasley Allen in Montgomery, Alabama; Leonard Davis of Herman Herman & Katz in New Orleans; Gerald Meunier of Gainsburgh, Benjamin, David, Meunier & Warshauer, also in New Orleans; and Levin Sedran & Berman attorney Michael Weinkowitz in Philadelphia to form what the judge referred to as a “fee allocation liaison counsel” in the Xarelto litigation. The attorneys will be tasked with coming up with a recommendation for how the court should divide up the common benefit fund…. Read more
The judge presiding over a case which saw Johnson & Johnson hit with an $8bn jury verdict has reduced the amount the company has to pay in damages to $6.8m. Last October, J&J was ordered to pay $8bn in damages to a US man who claims he was not warned that taking the company’s antipsychotic Risperdal could lead to breast growth. A jury in Philadelphia agreed with the allegation that J&J’s Janssen unit had downplayed the risk that use of Risperdal (risperidone) in male children can cause enlarged breasts, a condition known as gynaecomastia…. Read more
On remand from the U.S. Supreme Court, the U.S. Court of Appeals for the Third Circuit has in turn remanded the case to the district court to determine whether state law claims are preempted by federal law in the 500+ lawsuits pending regarding the medication Fosamax in Merck Sharpe & Dohme v. Albrecht. As previously discussed on this blog in May 2019, the United States Supreme Court held that the issue of federal preemption is one to be decided by the court and not a jury, while somewhat clarifying the “clear evidence” standard governing the analysis. After the high court’s decision, it was unclear whether the Third Circuit would remand the cases to the district court for application of the Supreme Court’s guidance or decide the issue – a legal one, after all, as just declared by the Supreme Court – itself de novo. Following supplemental briefing by the parties,… Read more
Johnson & Johnson is facing tens of thousands of product liability lawsuits, involving, among other things, its antipsychotic drug Risperdal, opioids, vaginal mesh, and talcum powder. Here, Stanford Law Professor Nora Freeman Engstrom, a tort law and complex litigation expert, and Diana Garnet Li, a student in the Stanford Law School Class of 2021, discuss the mounting product liability exposure facing the multinational giant—and how these cases may develop…. Read more
$8 Billion Award in Risperdal Lawsuit  WebMD… Read more
Johnson & Johnson must pay $8 billion to Maryland man over Risperdal case, jury rules  The Washington Post… Read more
Johnson & Johnson gets another black eye in court, and its troubles are not over  The Washington Post… Read more
Johnson & Johnson has to pay $8 billion after male breast growth linked to antipsychotic drug, jury says  CNN… Read more
Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit  The New York Times… Read more
Johnson & Johnson, Risperdal maker hit with $8B verdict  NBC News… Read more
Johnson & Johnson reaches $20.4 million settlement in huge opioid case  The Washington Post… Read more
A division of Swiss pharmaceutical maker Novartis is halting distribution of generic Zantac pills over concerns about an ingredient possibly linked to cancer. Novartis-owned Sandoz has issued a "precautionary distribution stop" of all medicines containing ranitidine, an antacid and antihistamine used to block stomach acid. The stop "in all our markets will remain in place" until "further clarification," Novartis said. "Our internal investigation is ongoing to determine further details," the company said. The move came after the Food and Drug Administration last week said it had detected low levels of a probable carcinogen in the heartburn drug Zantac and its generic versions. Test findings:FDA finds probable carcinogen in Zantac and other heartburn drugs The probable carcinogen, called NDMA, has also prompted the recall of several … Read more
After years of limited guidance, the Supreme Court has finally provided direction to lower courts on the issue of preemption when they delivered their opinion in Merck v. Albrecht. “Preemption” is a common defense used by defendants in pharmaceutical mass tort litigation. Through this defense, pharmaceutical companies argue that the state law causes of action are preempted by the Food and Drug Administration’s (FDA) control over drug and medical device approval and labeling. The Preemption Defense The Merck v. Albrecht case centers the drug, Fosamax, as a focal point in the mass tort litigation. Fosamax is pharmaceutical used for osteoporosis treatment and the case revolves around atypical femur fractures caused by use of the osteoporosis drug. Merck, the maker of Fosamax, asserted the preemption defense. Merck argued that it was the state’s failure to warn consumers of the drug’s risk and causes of action could not be brought against Merck… Read more
A substance that could cause cancer has been found in some ranitidine heartburn and ulcer medicines, including the brand-name drug Zantac, and the source of this contamination is being investigated, the U.S. Food and Drug Administration says. While preliminary tests found low levels of the nitrosamine impurity N-nitrosodimethylamine (NDMA) in some ranitidine products, the FDA said this does not mean patients taking the drugs should stop using them now. NDMA is the same contaminant found in many brands of blood pressure and heart failure medicines during the past year, leading to recalls. Patients who are taking prescription ranitidine and want to stop using it should discuss alternatives with their health care provider, the FDA advised. Those taking over-the-counter (OTC) ranitidine could switch to other OTC … Read more
Tentative deal reached with Purdue Pharma, maker of OxyContin  The Washington Post… Read more
How significant is J&J's $572M opioid verdict in Oklahoma? It's complicated  FiercePharma… Read more
Johnson & Johnson has been facing several lawsuits over its different products, including talc, hip-plants, and the blood thinner, Xarelto. There are a total of around 50,000 such cases against the company. The company has agreed to settle several of these cases, as announced over the last few months. However, if it were to settle all of the above 50,000 cases, it would cost the company an amount north of $6 billion, in our view. Johnson & Johnson is capable of settling all the claims if need be from its cash in hand of $14 billion. View our interactive dashboard analysis ~ How Much Money Could Johnson & Johnson Have To Shell Out To Settle Its Lawsuits? … Read more
Texas Opioid MDL Gets 2020 Trial Dates  Law360… Read more
Pa. Judge Greenlights State's 1st Opioid Marketing Case  Law360… Read more
The US Supreme Court vacated and remanded a products liability case involving claims alleging a failure to warn about risks of stress fractures related to the use of Fosamax, which is manufactured by Merck Sharpe & Dohme Corp. (“Merck”). Fosamax is a drug that treats and prevents osteoporosis in post-menopausal women. Merck argued that the claims should be dismissed as they submitted “clear evidence” that FDA regulations prohibited them from changing the Fosamax label to include the stress fracture risk warnings. The Supreme Court held that the Third Circuit incorrectly determined that “clear evidence” is a question of fact for a jury; rather, the Court held that “clear evidence” is a question of law as it involves a legal determination about an agency decision. The FDA approved the sale of Fosamax in 1995. At that time, the Fosamax label did not warn of the risk of atypical femoral fracture, a type of… Read more
Sackler family, accused of profiting from opioid crisis, sued by New Jersey  ABC News… Read more
Why did Teva ink an $85M deal to sidestep the Oklahoma opioid trial?  FiercePharma… Read more
The U.S. Supreme Court on Monday handed a victory to Merck & Co – at least for now – by throwing out a lower court ruling that had revived hundreds of lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision allowing the lawsuits to proceed even though federal regulators had rebuffed Merck when the company sought to add a warning to Fosamax’s label about the fracture risk. The decision added clarity to a defense used by drug makers against product liability claims in which they argue that such litigation is preempted under federal law and the U.S. Constitution when a federal agency takes certain actions, as the Food and Drug Administration did in this case. In a decision written by Justice Stephen… Read more
Purdue finally gets a judge to toss state AG's opioids case. Does it matter?  Reuters… Read more
Johnson & Johnson has lost several major lawsuits over allegations that asbestos in its talcum powder contributes to ovarian cancer. For example, in a 2018 lawsuit, a St. Louis jury awarded almost $4.7 billion in total damages to 22 women and their families. As a strategy, the company has tried to get 2,400 of its state-court cancer lawsuits transferred to a federal court in Delaware. This would allow it to develop a single defense strategy. However, U.S. District Judge Maryellen Noreika in Wilmington, Del. dismissed the request yesterday, “noting that the world’s largest maker of health care products is partly responsible for the boomlet of litigation over its transfer strategy that it now characterizes as a crisis,” reports Bloomberg. J&J hoped that by invoking the legal rights of its talc supplier, Imerys Talc America, now bankrupt, it would create quicker trials and claims resolutions. But Noreika stated in her decision, “J&J cannot establish an emergency…. Read more
Purdue's Sackler family wants global opioids settlement: Sackler lawyer Mary Jo White  CNBC… Read more
Johnson & Johnson and Bayer agreed Monday to pay $775 million to settle almost 25,000 lawsuits in connection to blood thinner Xarelto. Each company will pay 50 percent of the settlement, according to The New York Times. The payment ends both state and federal cases — the New Brunswick, New Jersey-based Johnson & Johnson jointly markets Xarelto with Bayer, which is based in Germany. Patients sued both companies, which failed to issue warnings regarding possible fatal bleeding episodes connected to taking Xarelto. Neither company accepted liability and actually won all six lawsuits that went to trial. “Even in the face of meritless allegations, and even while winning in court, complex litigation demands an enormous amount of time and resources,” the pharmaceutical division of Johnson & Johnson explained in a statement regarding the settlement…. Read more
Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed. The amount will be shared equally between the two companies that jointly developed the drug. Bayer and J&J do not admit liability under the agreement. The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs. Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information…. Read more
KEY POINTS Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed. The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs. Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information. Bayer and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed. The amount will be shared equally between the two companies that jointly developed the drug. Bayer and J&J do not admit liability under the agreement. The settlement will… Read more
Purdue Pharma And Other Drug Companies Fight Opioid Disclosure : Shots – Health News  NPR… Read more
Plaintiffs' lawyer calls opioid defendants 'thugs,' 'sociopaths,' judge issues warning  Reuters… Read more

See More

Scroll to Top